Immupharma Share News (IMM)

ImmuPharma progresses P140 clinical programme with FDA

(Sharecast News) - Drug discovery and development company ImmuPharma announced positive progress in its late-stage P140 clinical programme on Tuesday, for patients with chronic idiopathic demyelinating polyneuropathy (CIDP), a rare neurological disease with high medical need.

IN BRIEF: ImmuPharma shares up as FDA meeting for new drug confirmed

ImmuPharma PLC - London-based drug discovery and development company - Gets confirmation of a pre-investigational new drug meeting with the US Food & Drug Administration, which will take place on May 16. It concerns the phase 2/3 adaptive trial study protocol for P140 in chronic idiopathic demyelinating polyneuropathy. Says the CIDP market is expected to reach global sales of USD2.7 billion by 2029. CIDP is a rare acquired autoimmune disorder of peripheral nerve affecting about 50,000 individuals across the US and Europe.

AIM WINNERS & LOSERS: System1 rises after upturn in second half

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

LONDON MARKET OPEN: Stocks looking for direction before US inflation

(Alliance News) - Stock prices in London opened mixed on Wednesday, as caution prevailed ahead of a US inflation reading and minutes from the Federal Reserve's March meeting.

LONDON MARKET MIDDAY: Bank stocks get boost as SVB assets bought

(Alliance News) - Stock prices in London were higher at midday on Monday, as investor sentiment was lifted by the news that a US bank will buy more USD70 billion dollars of Silicon Valley Bank assets.

AIM WINNERS & LOSERS: ScotGold drops two-thirds as gold grade declines

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

ImmuPharma submits phase 2/3 protocol to US FDA for Lupuzor treatment

(Alliance News) - ImmuPharma PLC on Monday said it submitted a phase 2/3 clinical trial protocol to the US Food & Drug Administration testing the Lupuzor treatment for lupus patients.

ImmuPharma signs 12-month deal with Orano for use of peptide tech

(Alliance News) - ImmuPharma PLC on Monday said it has signed an initial collaboration agreement with Orano SA for its peptide technology.

ImmuPharma agrees study design with Avion for lupus programme Lupuzor

(Alliance News) - ImmuPharma PLC on Monday confirmed alongside its partner Avion Pharmaceuticals that a phase 2/3 adaptive trial will be the best design for the next clinical study of Lupuzor in systemic lupus erythematosus patients.

TRADING UPDATES: Ground Rents Income Fund's portfolio value drops

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

TRADING UPDATES: Driver records loss; Synectics sells business unit

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

ImmuPharma upbeat after meeting with US partner Avion

(Sharecast News) - Drug discovery and development specialist ImmuPharma updated the market on a recent meeting in Atlanta with its United States partner Avion Pharmaceuticals on Friday, for strategic discussions around its 'Lupuzor' clinical programme.

TRADING UPDATES: ImmuPharma loss narrows; MetalNRG loss widens

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

UK earnings, trading statements calendar - next 7 days

ImmuPharma's US partner receives FDA response on Lupuzor

(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced on Wednesday that its US partner for 'Lupuzor', Avion Pharmaceuticals, has received a written response from the Food and Drug Administration (FDA).